|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
63,632,000 |
Market
Cap: |
1.59(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$24.98 - $24.98 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Provention Bio is a biopharmaceutical company. Co.'s pipeline of investigational candidates under development includes: PRV-031 (teplizumab), an anti-CD3 monoclonal antibody (mAb) for the delay of clinical Type 1 Diabetes (T1D); PRV-3279, a bispecific scaffold molecule targeting the B-cell surface proteins, FcgammaRIIb and CD79B, for the treatment of systemic lupus erythematosus; PRV-015 (ordesekimab), an anti-interleukin 15 mAb for the treatment of gluten-free diet non-responsive celiac disease; and PRV-101, a Coxsackie Virus B (CVB) vaccine to prevent acute CVB infections and to prevent the CVB-triggered autoimmune damage to pancreatic beta cells that may progress to T1D.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
0 |
0 |
0 |
5,594,666 |
Total Sell Value |
$0 |
$0 |
$0 |
$85,590,128 |
Total People Sold |
0 |
0 |
0 |
4 |
Total Sell Transactions |
0 |
0 |
0 |
13 |
End Date |
2024-03-17 |
2023-12-15 |
2023-06-16 |
2022-06-16 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Petry John |
10% Owner |
|
2023-04-27 |
4 |
D |
$0.00 |
$0 |
D/D |
(15,567,497) |
0 |
|
- |
|
Ramos Eleanor |
Chief Medical Officer |
|
2023-04-27 |
4 |
D |
$0.00 |
$0 |
D/D |
(70,000) |
0 |
|
- |
|
Leon Francisco |
Chief Scientific Officer |
|
2023-04-27 |
4 |
D |
$0.00 |
$0 |
I/I |
(2,500,000) |
0 |
|
- |
|
Leon Francisco |
Chief Scientific Officer |
|
2023-04-27 |
4 |
D |
$0.00 |
$0 |
D/D |
(73,000) |
0 |
|
- |
|
Pisano Wayne |
Director |
|
2023-04-27 |
4 |
D |
$0.00 |
$0 |
D/D |
(7,500) |
0 |
|
- |
|
Catlin Avery W |
Director |
|
2023-04-27 |
4 |
D |
$0.00 |
$0 |
I/I |
(20,000) |
0 |
|
- |
|
Palmer Ashleigh |
Director and CEO |
|
2023-04-27 |
4 |
D |
$0.00 |
$0 |
D/D |
(2,570,050) |
0 |
|
- |
|
Petry John |
10% Owner |
|
2023-04-21 |
4 |
GD |
$0.00 |
$0 |
D/D |
224,617 |
0 |
|
- |
|
Petry John |
10% Owner |
|
2023-04-20 |
4 |
GD |
$0.00 |
$0 |
D/D |
202,314 |
224,617 |
|
- |
|
Petry John |
10% Owner |
|
2023-04-14 |
4 |
S |
$24.32 |
$53,274,152 |
D/D |
(2,190,549) |
15,567,497 |
|
-3% |
|
Petry John |
10% Owner |
|
2023-04-14 |
4 |
OE |
$6.00 |
$53,274,138 |
D/D |
8,879,023 |
17,758,046 |
|
- |
|
Catlin Avery W |
Director |
|
2023-04-13 |
4 |
GA |
$0.00 |
$0 |
I/I |
10,000 |
10,000 |
|
- |
|
Catlin Avery W |
Director |
|
2023-04-13 |
4 |
GD |
$0.00 |
$0 |
D/D |
10,000 |
10,000 |
|
- |
|
Leon Francisco |
Chief Scientific Officer |
|
2023-04-13 |
4 |
GA |
$0.00 |
$0 |
I/I |
1,500,000 |
73,000 |
|
- |
|
Leon Francisco |
Chief Scientific Officer |
|
2023-04-13 |
4 |
GD |
$0.00 |
$0 |
D/D |
1,500,000 |
73,000 |
|
- |
|
Palmer Ashleigh |
Director and CEO |
|
2023-02-13 |
4 |
AS |
$10.04 |
$259,448 |
D/D |
(25,835) |
2,570,050 |
|
152% |
|
Palmer Ashleigh |
Director and CEO |
|
2023-02-13 |
4 |
OE |
$2.50 |
$64,588 |
D/D |
25,835 |
2,595,885 |
|
- |
|
Leon Francisco |
Chief Scientific Officer |
|
2023-02-13 |
4 |
AS |
$10.04 |
$260,944 |
D/D |
(25,985) |
1,573,000 |
|
152% |
|
Leon Francisco |
Chief Scientific Officer |
|
2023-02-13 |
4 |
OE |
$2.50 |
$64,963 |
D/D |
25,985 |
1,598,985 |
|
- |
|
Palmer Ashleigh |
Director and CEO |
|
2023-02-10 |
4 |
AS |
$10.11 |
$505,555 |
D/D |
(50,000) |
2,570,050 |
|
140% |
|
Palmer Ashleigh |
Director and CEO |
|
2023-02-10 |
4 |
OE |
$2.50 |
$125,000 |
D/D |
50,000 |
2,620,050 |
|
- |
|
Hoitt Jason |
Chief Commercial Officer |
|
2023-02-10 |
4 |
AS |
$10.00 |
$45,005 |
D/D |
(4,500) |
0 |
|
140% |
|
Leon Francisco |
Chief Scientific Officer |
|
2023-02-10 |
4 |
AS |
$10.11 |
$505,605 |
D/D |
(50,000) |
1,573,000 |
|
140% |
|
Leon Francisco |
Chief Scientific Officer |
|
2023-02-10 |
4 |
OE |
$2.50 |
$125,000 |
D/D |
50,000 |
1,623,000 |
|
- |
|
Petry John |
10% Owner |
|
2023-01-18 |
4 |
S |
$9.40 |
$28,200,000 |
D/D |
(3,000,000) |
11,879,023 |
|
-177% |
|
94 Records found
|
|
Page 1 of 4 |
|
|